Supreme Court: Borrowers Retain Redemption Rights if Balance is Paid After Auction Deadline || Supreme Court: Non-Confirmation of Seizure under Section 37A Impacts Adjudication Proceedings || SC: Blacklisting After Contract Termination is Not Automatic and Needs Independent Review || Grand Venice Fraud Case: Supreme Court Cancels Bail of Satinder Singh Bhasin || SC: Senior Employee Cannot Claim Same Lesser Penalty As Subordinate; Bank Manager's Dismissal Upheld || Madras HC: Governor Must Follow Cabinet's Advice on Remission Decisions, Regardless of Personal View || Kerala High Court: Entrepreneurs Must Be Protected From Baseless Protests to Boost Industrial Growth || J&K&L High Court: Second FIR Valid if it Reveals a Broader Conspiracy; 'Test of Sameness' is Key || Supreme Court: Expecting a Minor to Respond to a Public Court Notice is ‘Perverse’ || SC: Order 23 Rule 1 CPC Applies to S. 11 Arbitration Act, Barring Fresh Arbiration After Abandonment

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :